GLP-1 receptor agonists may be associated with improved survival outcomes and lower recurrence rates among women with breast cancer, obesity, and type 2 diabetes.
Bernard Fuemmeler, PhD, MPH
Advertisement
Articles by Bernard Fuemmeler, PhD, MPH
Emerging evidence links GLP-1 receptor agonists to improved breast cancer outcomes and the growing importance of metabolic health in survivorship care.
Researchers discuss how GLP-1 receptor agonists may be associated with improved survival outcomes in breast cancer and what clinicians should consider as use of these therapies continues to grow.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Closing the Kidney Gap in Cardio-Kidney-Metabolic Care
2
FDA Approves At-Home Starting Dose of Lecanemab for Treatment of Alzheimer Disease
3
Pharmacists Can Catch Missed CKD With One Question
4
GLP-1 RAs Linked to Lower Mortality, Amputation Risk in Patients With PAD and Type 2 Diabetes
5